Drug Profile
Glatiramer acetate - Biocad
Alternative Names: BCD-063Latest Information Update: 18 Feb 2022
Price :
$50
*
At a glance
- Originator Biocad
- Class Peptides; Polymers
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 18 Feb 2022 Discontinued - Phase-III for Multiple sclerosis (Second-line therapy or greater) in Russia (SC)
- 14 Sep 2016 Efficacy data from a phase III trial in multiple sclerosis (Second-line therapy or greater) released by Biocad
- 01 Oct 2013 Phase-III clinical trials in Multiple sclerosis (Second-line therapy or greater) in Russia (SC) (NCT02753088)